Stockreport

Cerus' soars on meeting main goal of late stage trial for INTERCEPT RBCs in heart surgery patients [Seeking Alpha]

Cerus Corporation  (CERS) 
Last cerus corporation earnings: 2/20 04:01 pm Check Earnings Report
PDF The trial demonstrated non-inferiority of the incidence of acute kidney injury for INTERCEPT Red Blood Cells compared to conventional red blood cells The safety endpo [Read more]